๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

GLP-1R Agonist Liraglutide Activates Cytoprotective Pathways and Improves Outcomes After Experimental Myocardial Infarction in Mice

โœ Scribed by Noyan-Ashraf, M. H.; Momen, M. A.; Ban, K.; Sadi, A.-M.; Zhou, Y.-Q.; Riazi, A. M.; Baggio, L. L.; Henkelman, R. M.; Husain, M.; Drucker, D. J.


Book ID
125990863
Publisher
American Diabetes Association
Year
2009
Tongue
English
Weight
370 KB
Volume
58
Category
Article
ISSN
0012-1797

No coin nor oath required. For personal study only.


๐Ÿ“œ SIMILAR VOLUMES


GLP-1R Agonist Liraglutide Activates Cyt
โœ Noyan-Ashraf, M. H.; Momen, M. A.; Ban, K.; Sadi, A.-M.; Zhou, Y.-Q.; Riazi, A. ๐Ÿ“‚ Article ๐Ÿ“… 2009 ๐Ÿ› American Diabetes Association ๐ŸŒ English โš– 370 KB

## OBJECTIVE Glucagon-like peptide-1 receptor (GLP-1R) agonists are used to treat type 2 diabetes, and transient GLP-1 administration improved cardiac function in humans after acute myocardial infarction (MI) and percutaneous revascularization. However, the consequences of GLP-1R activation before